klow peptide clinical trial BLEND What Evidence Supports Klow's Impact
Description
He and colleagues identified eight FRGs, including N-Ras, epithelial membrane protein 1 (EMP1), MYC, Mucin 1 (MUC1), and GABA Type A Receptor Associated Protein Like 1 (GABARAPL1) in BALF of IPF patients [205]
A peculiar VNTR in the cystathionine beta-synthase gene is a risk factor for Down Syndrome
Follow-up Repeat metabolic markers after 4-12 weeks, with closer review during dose escalation or major appetite changes
doi: 10.1158/1078-0432.CCR-03-0666
